Brand Name | Status | Last Update |
---|---|---|
arbli | New Drug Application | 2025-03-20 |
cozaar | New Drug Application | 2024-11-20 |
hyzaar | New Drug Application | 2024-11-11 |
losartan | ANDA | 2018-02-15 |
losartan pot/hctz | ANDA | 2019-08-02 |
losartan potassium | ANDA | 2025-03-21 |
losartan potassium and hydrochlorothiazide | ANDA | 2025-01-21 |
losartan potassium and hydrochlorothiazide | ANDA | 2025-03-04 |
losartan potassium and hydrochlorothiazide losartan potassium hctz | ANDA | 2019-10-14 |
losartan potassium losartan potassium | ANDA | 2023-01-07 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Losartan |
INN | losartan |
Description | Losartan is a biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an endothelin receptor antagonist and an anti-arrhythmia drug. It is a biphenylyltetrazole and a member of imidazoles. It is a conjugate acid of a losartan(1-). |
Classification | Small molecule |
Drug class | angiotensin II receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1 |
PDB | — |
CAS-ID | 114798-26-4 |
RxCUI | — |
ChEMBL ID | CHEMBL191 |
ChEBI ID | 6541 |
PubChem CID | 3961 |
DrugBank | DB00678 |
UNII ID | JMS50MPO89 (ChemIDplus, GSRS) |